v3.25.1

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2025	Dec. 31, 2024
Current Assets
Cash and cash equivalents	$ 1,028,342	$ 662,517
Accounts receivable, net	93,449	100,285
Inventory	215,696	58,319
Prepaid expense	1,435	4,832
Overpayment to related parties	0	21,798
Total current assets	1,338,922	847,751
Other Assets
Intangible assets	56,037	26,037
Total Assets	1,394,959	873,788
Current Liabilities
Accounts payable	16,415	8,226
Accrued expenses	20,750	5,993
Deferred revenue	50,038	24,329
Total current liabilities	132,921	38,548
STOCKHOLDERS’ EQUITY (DEFICIT)
Series A Convertible Preferred Stock, 1,000,000 designated, 140,000 shares issued and outstanding at December 31, 2024 and 2023, respectively	14	14
Common stock: $0.0001 par value, 75,000,000 shares authorized; 43,916,221 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	4,391	4,391
Additional paid-in capital	1,171,918	1,171,918
Accumulated earnings (deficit)	85,715	(341,083)
Total stockholders’ equity (deficit)	1,262,038	835,240
Total Liabilities and Stockholders’ Equity (Deficit)	1,394,959	873,788
Related Party [Member]
Current Liabilities
Due to related parties	$ 45,718	$ 0

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

BioScience Health Innovations, Inc. 10-Q